8-K/AAcquisitions & DispositionsExhibits & Filings

QUEST DIAGNOSTICS INC 8-K/A Report, Acquisition Completed (Jan 17, 2006)

Filed January 17, 2006For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an amendment to its Form 8-K on January 17, 2006, primarily to provide updated financial information related to the acquisition of LabOne, Inc. This amendment ensures compliance with SEC regulations by including the necessary financial statements and pro forma combined financial information. Investors should note that this filing is an amendment to an earlier report dated October 31, 2005, and its purpose is to formally incorporate the financial details of the acquired entity, LabOne, Inc., which is crucial for understanding the financial impact of this significant transaction on Quest Diagnostics. The core of this filing lies in the supplementary exhibits. These include detailed financial statements for LabOne, Inc. covering periods up to December 31, 2004, and interim periods ending September 30, 2005. Additionally, pro forma combined financial information for Quest Diagnostics, reflecting the acquisition's impact as of September 30, 2005, and for the nine months ended September 30, 2005, and the fiscal year ended December 31, 2004, is provided. This comprehensive financial data is essential for investors to assess the accretion or dilution resulting from the LabOne acquisition and to evaluate Quest Diagnostics' post-acquisition financial position and performance.

Key Highlights

  • 1Quest Diagnostics filed an amendment (8-K/A) on January 17, 2006, to a previous report filed on October 31, 2005.
  • 2The amendment's primary purpose is to provide required financial statements and pro forma information related to the acquisition of LabOne, Inc.
  • 3Exhibit 99.1 includes detailed financial statements for LabOne, Inc. for the years ended December 31, 2004, 2003, and 2002.
  • 4Exhibit 99.2 provides LabOne, Inc.'s financial statements for the period ending September 30, 2005, including year-to-date and comparative prior year periods.
  • 5Exhibit 99.3 presents unaudited pro forma combined financial information for Quest Diagnostics as of September 30, 2005, and for the nine months ended September 30, 2005, and the year ended December 31, 2004.
  • 6This filing is crucial for investors to assess the financial implications and integration of the LabOne, Inc. acquisition.
  • 7The filing was signed by Robert A. Hagemann, Senior Vice President and Chief Financial Officer.

Frequently Asked Questions

The main purpose of this amended 8-K filing is to formally include the required financial statements of the acquired company, LabOne, Inc., and pro forma combined financial information for Quest Diagnostics. This was necessary to comply with SEC regulations following the acquisition.

The filing includes detailed historical financial statements for LabOne, Inc. for various periods up to December 31, 2004, and interim periods ending September 30, 2005. It also provides unaudited pro forma combined financial statements for Quest Diagnostics, reflecting the impact of the LabOne acquisition as of September 30, 2005, and for the nine-month period then ended and the fiscal year 2004.

The pro forma financial information is crucial for investors as it shows how Quest Diagnostics' financial statements would look if the acquisition of LabOne, Inc. had occurred at an earlier date. This helps investors understand the combined entity's financial performance and position, assess potential synergies, and evaluate the acquisition's impact on earnings per share.

No, this filing is specifically an amendment to provide historical financial statements and pro forma data related to the LabOne, Inc. acquisition. It does not contain new operational strategies, business outlooks, or management commentary beyond what is required for the financial disclosures.